Neonc Technologies (NASDAQ:NTHI) CEO Buys $209,500.00 in Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour acquired 50,000 shares of Neonc Technologies stock in a transaction on Tuesday, November 10th. The stock was purchased at an average cost of $4.19 per share, for a total transaction of $209,500.00. Following the purchase, the chief executive officer owned 3,313,000 shares in the company, valued at approximately $13,881,470. The trade was a 1.53% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Neonc Technologies Stock Up 1.2%

Shares of NTHI traded up $0.06 during mid-day trading on Friday, hitting $4.91. 251,853 shares of the stock were exchanged, compared to its average volume of 118,828. Neonc Technologies Holdings, Inc. has a 52-week low of $2.50 and a 52-week high of $11.38. The firm has a 50-day moving average of $3.30 and a two-hundred day moving average of $5.27.

Neonc Technologies (NASDAQ:NTHI) last posted its earnings results on Thursday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03).

Analyst Upgrades and Downgrades

NTHI has been the topic of a number of recent research reports. BTIG Research reaffirmed a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a research note on Tuesday, September 8th. Wall Street Zen raised shares of Neonc Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Zacks Research upgraded shares of Neonc Technologies from a “strong sell” rating to a “hold” rating in a report on Thursday, November 5th. Roth Capital began coverage on shares of Neonc Technologies in a report on Thursday, September 24th. They issued a “buy” rating on the stock. Finally, Weiss Ratings cut shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.00.

Hedge Funds Weigh In On Neonc Technologies

Large investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in Neonc Technologies by 5.0% in the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock worth $1,650,000 after purchasing an additional 11,108 shares during the period. Westmount Partners LLC lifted its stake in shares of Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Neonc Technologies during the second quarter valued at $815,000. Marshall Wace LLP boosted its stake in shares of Neonc Technologies by 423.5% during the third quarter. Marshall Wace LLP now owns 114,046 shares of the company’s stock valued at $388,000 after purchasing an additional 92,262 shares during the period. Finally, Global Retirement Partners LLC purchased a new stake in shares of Neonc Technologies during the second quarter valued at $126,000.

About Neonc Technologies

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.